Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly misrepresenting the company's development progress and overstating achievements in prostate cancer therapeutics during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against the Company - The allegations state that Telix misrepresented its development progress and the reliability of its supply chain and partners, leading to materially false or misleading statements about its business and operations [3]. - The disclosure of the truth regarding the company's business resulted in significant losses for investors [3].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly misrepresenting the company's development progress and overstating achievements in prostate cancer therapeutics during the Class Period from February 21, 2025, to August 28, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities during the specified Class Period [1]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations - The complaint alleges that the defendants misrepresented the company's business operations, including the reliability of its supply chain and partners, leading to materially false or misleading statements [3]. - As a result of these misrepresentations, investors experienced significant losses when the truth about the company's business was revealed [3]. Group 3: Company Background - Telix Pharmaceuticals is based in Melbourne, Australia, and focuses on radiopharmaceutical therapies and diagnostics for oncology [2].

PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...